Commerce Secretary Lutnick says he is confident US will secure trade deal with EU
Lutnick said he had just gotten off the phone with European trade negotiators and there was "plenty of room" for agreement.
"These are the two biggest trading partners in the world, talking to each other. We'll get a deal done. I am confident we'll get a deal done," Lutnick said in an interview with CBS' "Face the Nation."
U.S. President Donald Trump threatened on July 12 to impose a 30% tariff on imports from Mexico and the European Union starting on August 1, after weeks of negotiations with the major U.S. trading partners failed to reach a comprehensive trade deal.
Lutnick said that was a hard deadline.
"Nothing stops countries from talking to us after August 1, but they're going to start paying the tariffs on August 1," he said on CBS.
Trump announced the tariffs in a letter to European Commission President Ursula von der Leyen. He sent letters to other trading partners including Mexico, Canada, Japan and Brazil, setting blanket tariff rates ranging from 20% to 50%, as well as a 50% tariff on copper.
Lutnick also said he expected Trump to renegotiate the United States-Mexico-Canada Agreement (USMCA) signed during Trump's first White House term in 2017-21.
Barring any major changes, USMCA-compliant goods from Mexico and Canada are exempt from tariffs.
"I think the president is absolutely going to renegotiate USMCA, but that's a year from today," Lutnick said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
20 minutes ago
- Reuters
Gold eases from one-month high on firmer dollar, profit-taking
July 22 (Reuters) - Gold prices eased on Tuesday from their highest level in more than a month, pressured by profit-taking and a slight rebound in the dollar, while investors looked for progress in trade talks ahead of an August 1 deadline. Spot gold was down 0.3% at $3,384.49 per ounce, as of 0656 GMT. Earlier in the session, bullion hit its highest level since June 17. U.S. gold futures also slipped 0.3% to $3,397. "Gold's move on the upside has been pretty much supported by positive technicals and as well as reinforced by a broad base of dollar weakness," OANDA senior market analyst Kelvin Wong said. The dollar index (.DXY), opens new tab edged 0.1% higher after falling to a more than one-week low on Monday, making greenback-priced gold more expensive for other currency holders. The European Union is exploring a broader set of possible countermeasures against the United States as prospects for an acceptable trade agreement with Washington fade, according to EU diplomats. U.S. President Donald Trump has threatened 30% duties on imports from Europe if no agreement is signed before the August 1 deadline. "There could be a possibility that U.S. and the respective trading partners may not agree to the terms and condition and that potentially could see a bit of uncertainty and there could be some hedging activities by market participants going forward," Wong said. Also on radar, the European Central Bank is expected to hold interest rates steady at 2.0% following a string of cuts at the end of its policy meeting on July 24. The U.S. Federal Reserve's monetary policy meeting is scheduled for next week. Traders are pricing about a 59% chance of a rate cut by the Fed in September, according to the CME FedWatch Tool. Gold tends to perform well in a low-interest-rate environment. Spot silver dipped 0.1% to $38.86 per ounce, platinum added 0.6% to $1,447.53 and palladium gained 0.2% to $1,266.95.
The Guardian
an hour ago
- The Guardian
AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats
AstraZeneca has announced it will invest $50bn (£37bn) in the US by 2030, the latest in a string of pledges by pharmaceutical companies as the threat of Donald Trump's tariffs looms over the industry. The British drugmaker, which is headquartered in Cambridge, said its investment will fund a new drug manufacturing facility in Virginia and expand its research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement comes as Trump threatens to impose tariffs of up to 200% on pharmaceuticals made outside the US. Drug companies could be given between 12and 18 months to bring their manufacturing to the US, the president said last month. Howard Lutnick, the US commerce secretary, said Trump's tariffs were focused on ending reliance on the foreign supply of key pharmaceutical products. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here,' he said. The AstraZeneca chief executive, Pascal Soriot, said the $50bn investment would support the company's ambition to reach $80bn in revenue by 2030, at which point 50% of sales are expected to come from the US. The company brought in $54.1bn in revenues in 2024. AstraZeneca joins a long list of companies unveiling investments in the US in the face of potentially punitive tariffs. The Swiss drugmaker Roche announced in April that it would put $50bn in US manufacturing over the next five years, in a move it claimed would create more than 12,000 jobs. Its rival Novartis has said it will spend $23bn in the US, and the American pharmaceutical company Johnson & Johnson said in March that it would invest $55bn in manufacturing and research and development. The Trump administration has already launched an investigation into the pharmaceutical industry, arguing that foreign imports threaten national security, as well as 'most favoured nation' pricing. He said in May that the US would 'no longer tolerate profiteering and price gouging from big pharma'. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion Technology companies have also strengthened their commitments to the US, amid rising political pressure. In February Apple announced it would invest $500bn in the US over the next four years, including a giant factory in Texas for artificial intelligence servers. AstraZeneca's multibillion-dollar commitment to the US follows a report by the Times that Soriot – one of the highest paid executives in the FTSE 100 – would like to shift the company's stock market listing from London to New York. Such a move would deal a big blow to the UK stock market, which has already suffered a series of departures by companies seeking higher valuations. The pharmaceutical company is one of the biggest businesses listed in London, with a market value of £158.7bn.
Reuters
an hour ago
- Reuters
Thailand's next central bank chief champions rate cuts to revive growth
BANGKOK, July 22 (Reuters) - Vitai Ratanakorn, the incoming governor of the Bank of Thailand, by his own admission, will start his new job in October at a difficult time. Growth in Southeast Asia's second-largest economy has stalled, tense negotiations with the United States over trade tariffs continue, industrial sentiment is tepid and critical sectors, including tourism and manufacturing, aren't firing. "We must accept that the Thai economy is not doing so well," Vitai, who has been approved by the cabinet as the next central bank chief but awaits royal endorsement, told reporters last week. "And what is worrying is the sluggishness that may be prolonged." The 54-year-old, who currently serves as president and chief executive of the Government Savings Bank, Thailand's largest state-owned lender, has a prescription: more rate cuts. The central bank late last month left the key interest rate unchanged, underlining the need to save some policy ammunition, after cuts in October, February and April. Those reductions brought the one-day repurchase rate (THCBIR=ECI), opens new tab to 1.75%, the lowest in more than two years. "Proactive easing is important," Vitai told Thai financial daily Krungthep Turakij on June 20, when he was locked in the race for the top job with central bank insider Roong Mallikamas. "It's not just another one or two cuts. We may have to reduce them for a long time and more deeply. So, from 1.75%, if you ask me personally, I think it can go down much further." Thailand's ruling Pheu Thai party, which took power in 2023, has been at loggerheads with current Bank of Thailand chief Sethaput Suthiwartnarueput for not cutting rates enough to support a sluggish economy. In May last year, before she became prime minister, Pheu Thai leader Paetongtarn Shinawatra said the central bank's independence was an "obstacle" in resolving economic problems, underlining the scale of the friction. Vitai's stance will likely tone down some of that conflict, but it has also raised questions about his own ability to lead the central bank without succumbing to pressure from the ruling party - an issue he has publicly addressed. "I am confident that I can make decisions independently, based on principles and prioritising the nation's interests, free from the influence of any groups," Vitai wrote on his Facebook page on July 8. Vitai studied economics and law at Thailand's Chulalongkorn and Thammasat universities, and finance at Drexel University in the United States, and entered the Thai private sector, where he worked at Charoen Pokphand Group and budget carrier Nok Air. A former colleague, who worked alongside Vitai at a private firm, described him as a team player who preferred to work with consensus. "He is more of a practicalist than a theorist, focusing on getting the job done," he said, asking not to be named because he is not authorised to speak to media. In 2018, Vitai was appointed the Secretary-General of the Government Pension Fund, which manages assets worth about 1.4 trillion baht ($43 billion), and two years later became the head of the Government Savings Bank. Thirachai Phuvanatnaranubala, a former Thai finance minister, said Vitai's long experience as a government banker should help him manage relationships with senior finance ministry leadership. "However, his lack of work experience and zero exposure to high level macro public policy is a cause for concern," Thirachai told Reuters.
